Analysis of laboratory outcomes in assisted reproductive technology for malignant tumor patients
10.3760/cma.j.cn101441-20240912-00338
- VernacularTitle:恶性肿瘤患者辅助生殖助孕实验室结局分析
- Author:
Ran SHEN
1
;
Wei ZHENG
1
;
Ruowen ZU
1
;
Chen YANG
1
;
Bingnan REN
1
;
Jiaheng LI
1
;
Yanli LIU
1
;
Jing LI
1
;
Peixin LI
1
;
Jingyi HAN
1
;
Yichun GUAN
1
Author Information
1. 郑州大学第三附属医院生殖健康医院，郑州 450052
- Publication Type:Journal Article
- Keywords:
Fertility preservation;
Malignant tumor;
Controlled ovarian hyperstimulation;
Fertilization in vitro;
Sperm injections, intracytoplasmic
- From:
Chinese Journal of Reproduction and Contraception
2025;45(4):365-371
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate whether malignant tumors affect the laboratory outcomes of patients in their first controlled ovarian hyperstimulation (COH) cycle.Methods:This study was a retrospective case-control study that analyzed the clinical and laboratory data of patients who underwent fertility preservation before chemotherapy and radiotherapy due to malignant tumors, as well as patients with infertility caused by tubal factors who first underwent in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the Reproductive Health Hospital of the Third Affiliated Hospital of Zhengzhou University from January 2020 to May 2024. Patients who underwent fertility preservation were designated as the research group, while patients who underwent assisted reproduction due to tubal factors during the same period were designated as control group. After 1∶3 propensity score matching (PSM), 40 patients were included in the research group and 118 patients were included in control group. The ovarian response, oocyte retrieval outcomes, and embryonic development after fertilization in the first COH cycle were compared between the two groups. Results:After PSM, the research group and control group showed statistically significant differences in the gonadotropin (Gn) starting dosage [225.00 (162.50, 300.00) U vs. 193.75 (150.00, 225.00) U, P=0.002], duration of Gn used [10.00 (8.00, 11.00) d vs. 12.00 (10.00, 13.00) d, P<0.001], and average estradiol levels on human chorionic gonadotropin trigger day [2 487.00 (1 461.25, 4 090.25) pmol/L vs. 10 738.50 (8 400.00, 16 507.25) pmol/L, P<0.001]. However, no statistically significant difference was found in the total dosages of Gn used between the two groups ( P>0.05). There were no significant differences between the groups in terms of the number of oocytes retrieved, the number of metaphase Ⅱ oocytes, two pronuclei (2PN) rate, 2PN cleavage rate, available embryo rate, high-quality embryo rate, blastocyst formation rate, and available blastocyst formation rate (all P>0.05). Conclusion:Compared with infertility patients with tubal factors, there is no significant difference in the laboratory outcomes of malignant tumor patients undergoing COH for fertility preservation prior to chemotherapy and radiation.
